Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CBX7 | O95931 | 1/20 | 0.35 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.35 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.35 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31123312 | 0.88 | CNR2 (0.38) | BCL6CNR2MEN1KMT2AEGFR | |
| SCHEMBL29209022 | 0.88 | CNR2 (0.38) | BCL6CNR2MEN1KMT2AEGFR | |
| SCHEMBL24865705 | 0.88 | CNR2 (0.39) | BCL6CNR2MEN1KMT2ACBX7 | |
| SCHEMBL24865368 | 0.87 | EGFR (0.45) | BCL6CNR2CBX7CDYL2CDYL | |
| SCHEMBL24865798 | 0.86 | HTR1A (0.38) | BCL6MEN1KMT2AEGFRSRC | |
| SCHEMBL24865740 | 0.85 | BCL6 (0.40) | BCL6CNR2MEN1KMT2A | |
| SCHEMBL31123195 | 0.84 | SLC6A2 (0.37) | BCL6MEN1KMT2AEGFRHTR1A | |
| SCHEMBL31123214 | 0.83 | BCL6 (0.49) | BCL6CNR2JAK2 | |
| SCHEMBL24865769 | 0.83 | BCL6 (0.49) | BCL6CNR2JAK2 | |
| SCHEMBL24864838 | 0.83 | TP53 (0.40) | BCL6CNR2MEN1KMT2AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | BCL6 390/4885SIGMAR1 2490/4885CNR2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.